Click here to get full coverage on FDA to review new tab-cel data after Atara partner seeks clarity - Stock Titan

FDA to review new tab-cel data after Atara partner seeks clarity  Stock Titan

FDA to review new tab-cel data after Atara partner seeks clarity - Stock Titan

Click here to get full coverage on Precision Trading with Atara Biotherapeutics Inc. (ATRA) Risk Zones - Stock Traders Daily

Precision Trading with Atara Biotherapeutics Inc. (ATRA) Risk Zones  Stock Traders Daily

Precision Trading with Atara Biotherapeutics Inc. (ATRA) Risk Zones - Stock Traders Daily

Click here to get full coverage on Atara (ATRA) Schedules FDA Meeting to Address CRL for Tabelecleu - GuruFocus

Atara (ATRA) Schedules FDA Meeting to Address CRL for Tabelecleu  GuruFocus

Atara (ATRA) Schedules FDA Meeting to Address CRL for Tabelecleu - GuruFocus

Click here to get full coverage on ATRA FORM opens its Multisensorial New York Gallery - Design Milk

ATRA FORM opens its Multisensorial New York Gallery  Design Milk

ATRA FORM opens its Multisensorial New York Gallery - Design Milk

Click here to get full coverage on $ATRA stock is up 15% today. Here's what we see in our data. - Quiver Quantitative

$ATRA stock is up 15% today. Here's what we see in our data.  Quiver Quantitative

$ATRA stock is up 15% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Atra study provides rare, caveated glimpse into the U.S. rabbinate, offering insight and concern - eJewishPhilanthropy

Atra study provides rare, caveated glimpse into the U.S. rabbinate, offering insight and concern  eJewishPhilanthropy

Atra study provides rare, caveated glimpse into the U.S. rabbinate, offering insight and concern - eJewishPhilanthropy

Click here to get full coverage on New York Design Galleries - Trend Hunter

New York Design Galleries  Trend Hunter

New York Design Galleries - Trend Hunter

Click here to get full coverage on APOLLO: ATO-ATRA Improves Efficacy Over Standard ATRA + Chemotherapy in Newly Diagnosed High-Risk APL - ASCO Daily News

APOLLO: ATO-ATRA Improves Efficacy Over Standard ATRA + Chemotherapy in Newly Diagnosed High-Risk APL  ASCO Daily News

APOLLO: ATO-ATRA Improves Efficacy Over Standard ATRA + Chemotherapy in Newly Diagnosed High-Risk APL - ASCO Daily News

Click here to get full coverage on Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - PR Newswire

Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)  PR Newswire

Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - PR Newswire

Click here to get full coverage on UK Asset-Token Reporting Act: ATRA Guide for Crypto Investors - Bitget

UK Asset-Token Reporting Act: ATRA Guide for Crypto Investors  Bitget

UK Asset-Token Reporting Act: ATRA Guide for Crypto Investors - Bitget

Click here to get full coverage on Tim Passmore receives ATRA Distinguished Fellow Award - go.okstate.edu

Tim Passmore receives ATRA Distinguished Fellow Award  go.okstate.edu

Tim Passmore receives ATRA Distinguished Fellow Award - go.okstate.edu

Click here to get full coverage on Recreational Therapy Program Receives ATRA Excellence in Education Award - Old Dominion University

Recreational Therapy Program Receives ATRA Excellence in Education Award  Old Dominion University

Recreational Therapy Program Receives ATRA Excellence in Education Award - Old Dominion University

Click here to get full coverage on PIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION - PR Newswire

PIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION  PR Newswire

PIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION - PR Newswire

Click here to get full coverage on $ATRA stock is up 16% today. Here's what we see in our data. - Quiver Quantitative

$ATRA stock is up 16% today. Here's what we see in our data.  Quiver Quantitative

$ATRA stock is up 16% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Your Daily Phil: Who’s a rabbi these days? Inside Atra’s controversial study - eJewishPhilanthropy

Your Daily Phil: Who’s a rabbi these days? Inside Atra’s controversial study  eJewishPhilanthropy

Your Daily Phil: Who’s a rabbi these days? Inside Atra’s controversial study - eJewishPhilanthropy

Click here to get full coverage on Atra study’s data point on LGBTQ+ rabbinical students is a cause for celebration and hope — and a charge - eJewishPhilanthropy

Atra study’s data point on LGBTQ+ rabbinical students is a cause for celebration and hope — and a charge  eJewishPhilanthropy

Atra study’s data point on LGBTQ+ rabbinical students is a cause for celebration and hope — and a charge - eJewishPhilanthropy

Click here to get full coverage on Your Daily Phil: Atra’s leadership has been reading your op-eds - eJewishPhilanthropy

Your Daily Phil: Atra’s leadership has been reading your op-eds  eJewishPhilanthropy

Your Daily Phil: Atra’s leadership has been reading your op-eds - eJewishPhilanthropy

Click here to get full coverage on 3 ways to unpack Atra’s new rabbinic leadership study with your team - eJewishPhilanthropy

3 ways to unpack Atra’s new rabbinic leadership study with your team  eJewishPhilanthropy

3 ways to unpack Atra’s new rabbinic leadership study with your team - eJewishPhilanthropy

Click here to get full coverage on ATRA Stock Nearly Halves In Value After FDA Refuses Approval For Immunotherapy: Retail Sees ‘Big Fight Back’ - Stocktwits

ATRA Stock Nearly Halves In Value After FDA Refuses Approval For Immunotherapy: Retail Sees ‘Big Fight Back’  Stocktwits

ATRA Stock Nearly Halves In Value After FDA Refuses Approval For Immunotherapy: Retail Sees ‘Big Fight Back’ - Stocktwits

Click here to get full coverage on ‘I was shocked’: Three Minnesotans describe unexpected ICE detentions - Sahan Journal

‘I was shocked’: Three Minnesotans describe unexpected ICE detentions  Sahan Journal

‘I was shocked’: Three Minnesotans describe unexpected ICE detentions - Sahan Journal

Click here to get full coverage on T cells to suppress colorectal liver metastasis by stabilizing DDX5/STAT3/CXCL11 axis - Nature

T cells to suppress colorectal liver metastasis by stabilizing DDX5/STAT3/CXCL11 axis  Nature

T cells to suppress colorectal liver metastasis by stabilizing DDX5/STAT3/CXCL11 axis - Nature

Click here to get full coverage on ATRA Form Gallery’s Mythic Zona Maco Design Curation - surfacemag.com

ATRA Form Gallery’s Mythic Zona Maco Design Curation  surfacemag.com

ATRA Form Gallery’s Mythic Zona Maco Design Curation - surfacemag.com

Click here to get full coverage on Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains? - Yahoo Finance

Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains?  Yahoo Finance

Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains? - Yahoo Finance

Click here to get full coverage on Assessing the Impact of All-Trans Retinoic Acid (ATRA)- and Arsenic Trioxide (ATO)-Based Therapy in Pediatric Acute Promyelocytic Leukemia: A Single-Center Study - Cureus

Assessing the Impact of All-Trans Retinoic Acid (ATRA)- and Arsenic Trioxide (ATO)-Based Therapy in Pediatric Acute Promyelocytic Leukemia: A Single-Center Study  Cureus

Assessing the Impact of All-Trans Retinoic Acid (ATRA)- and Arsenic Trioxide (ATO)-Based Therapy in Pediatric Acute Promyelocytic Leukemia: A Single-Center Study - Cureus

Click here to get full coverage on Technical Reactions to ATRA Trends in Macro Strategies - Stock Traders Daily

Technical Reactions to ATRA Trends in Macro Strategies  Stock Traders Daily

Technical Reactions to ATRA Trends in Macro Strategies - Stock Traders Daily

Click here to get full coverage on Atara jumps on FDA’s U-turn on cell therapy (ATRA:NASDAQ) - Seeking Alpha

Atara jumps on FDA’s U-turn on cell therapy (ATRA:NASDAQ)  Seeking Alpha

Atara jumps on FDA’s U-turn on cell therapy (ATRA:NASDAQ) - Seeking Alpha

Click here to get full coverage on Atara (NASDAQ: ATRA) extends $9M HCRx payment and grants 400,000-share warrant - Stock Titan

Atara (NASDAQ: ATRA) extends $9M HCRx payment and grants 400,000-share warrant  Stock Titan

Atara (NASDAQ: ATRA) extends $9M HCRx payment and grants 400,000-share warrant - Stock Titan

Click here to get full coverage on Biotech Atara pushes $9M payment to 2028, grants 400,000-share warrant - Stock Titan

Biotech Atara pushes $9M payment to 2028, grants 400,000-share warrant  Stock Titan

Biotech Atara pushes $9M payment to 2028, grants 400,000-share warrant - Stock Titan

Click here to get full coverage on Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel) - Business Wire

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)  Business Wire

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel) - Business Wire

Click here to get full coverage on There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues - simplywall.st

There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues  simplywall.st

There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues - simplywall.st

Click here to get full coverage on ATRA flags eight 'judicial hellholes' - PropertyCasualty360

ATRA flags eight 'judicial hellholes'  PropertyCasualty360

ATRA flags eight 'judicial hellholes' - PropertyCasualty360

Click here to get full coverage on Modern treatment of acute promyelocytic leukemia - Haematologica

Modern treatment of acute promyelocytic leukemia  Haematologica

Modern treatment of acute promyelocytic leukemia - Haematologica

Click here to get full coverage on Atara Biotherapeutics: An Empty Pipeline With Little Gas (NASDAQ:ATRA) - Seeking Alpha

Atara Biotherapeutics: An Empty Pipeline With Little Gas (NASDAQ:ATRA)  Seeking Alpha

Atara Biotherapeutics: An Empty Pipeline With Little Gas (NASDAQ:ATRA) - Seeking Alpha

Click here to get full coverage on Atra, Pierre Augustin Rose Lead Latest Crop of Showrooms Elevating New York's Design Scene - Galerie Magazine

Atra, Pierre Augustin Rose Lead Latest Crop of Showrooms Elevating New York's Design Scene  Galerie Magazine

Atra, Pierre Augustin Rose Lead Latest Crop of Showrooms Elevating New York's Design Scene - Galerie Magazine

Click here to get full coverage on Atara Biotherapeutics Stock (ATRA) Jumps as FDA Decision on Viral Therapy Nears - TipRanks

Atara Biotherapeutics Stock (ATRA) Jumps as FDA Decision on Viral Therapy Nears  TipRanks

Atara Biotherapeutics Stock (ATRA) Jumps as FDA Decision on Viral Therapy Nears - TipRanks

Click here to get full coverage on Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel - Business Wire

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel  Business Wire

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel - Business Wire

Click here to get full coverage on A gigantic furry sofa anchors this new Manhattan furniture gallery - wallpaper.com

A gigantic furry sofa anchors this new Manhattan furniture gallery  wallpaper.com

A gigantic furry sofa anchors this new Manhattan furniture gallery - wallpaper.com

Click here to get full coverage on ATRA: Intelligence of Evolution - Dezeen

ATRA: Intelligence of Evolution  Dezeen

ATRA: Intelligence of Evolution - Dezeen

Click here to get full coverage on What the first major study of the US rabbinate reveals - Jewish Telegraphic Agency

What the first major study of the US rabbinate reveals  Jewish Telegraphic Agency

What the first major study of the US rabbinate reveals - Jewish Telegraphic Agency

Click here to get full coverage on Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - PR Newswire

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)  PR Newswire

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - PR Newswire

Click here to get full coverage on FDA says no to rare transplant cancer treatment patients awaited - Stock Titan

FDA says no to rare transplant cancer treatment patients awaited  Stock Titan

FDA says no to rare transplant cancer treatment patients awaited - Stock Titan

Click here to get full coverage on Atara Biotherapeutics (ATRA) Shares Rise Despite FDA Rejection - GuruFocus

Atara Biotherapeutics (ATRA) Shares Rise Despite FDA Rejection  GuruFocus

Atara Biotherapeutics (ATRA) Shares Rise Despite FDA Rejection - GuruFocus

Click here to get full coverage on Judicial System Breakdown Fuels Epidemic of Litigation Abuse, Report Warns - Risk & Insurance

Judicial System Breakdown Fuels Epidemic of Litigation Abuse, Report Warns  Risk & Insurance

Judicial System Breakdown Fuels Epidemic of Litigation Abuse, Report Warns - Risk & Insurance

Click here to get full coverage on While institutions own 28% of Atara Biotherapeutics, Inc. (NASDAQ:ATRA), individual investors are its largest shareholders with 35% ownership - Yahoo Finance

While institutions own 28% of Atara Biotherapeutics, Inc. (NASDAQ:ATRA), individual investors are its largest shareholders with 35% ownership  Yahoo Finance

While institutions own 28% of Atara Biotherapeutics, Inc. (NASDAQ:ATRA), individual investors are its largest shareholders with 35% ownership - Yahoo Finance

Click here to get full coverage on All-Trans Retinoic Acid and Arsenic Trioxide in High-Risk Acute Promyelocytic Leukemia - The ASCO Post

All-Trans Retinoic Acid and Arsenic Trioxide in High-Risk Acute Promyelocytic Leukemia  The ASCO Post

All-Trans Retinoic Acid and Arsenic Trioxide in High-Risk Acute Promyelocytic Leukemia - The ASCO Post

Click here to get full coverage on New Analyst Forecast: $ATRA Given $6 Price Target | ATRA Stock News - Quiver Quantitative

New Analyst Forecast: $ATRA Given $6 Price Target | ATRA Stock News  Quiver Quantitative

New Analyst Forecast: $ATRA Given $6 Price Target | ATRA Stock News - Quiver Quantitative

Click here to get full coverage on Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Is About To Turn The Corner - Yahoo Finance

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Is About To Turn The Corner  Yahoo Finance

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Is About To Turn The Corner - Yahoo Finance

Click here to get full coverage on Atara Biotherapeutics (ATRA) Adjusts Key Financial Agreement - GuruFocus

Atara Biotherapeutics (ATRA) Adjusts Key Financial Agreement  GuruFocus

Atara Biotherapeutics (ATRA) Adjusts Key Financial Agreement - GuruFocus

Click here to get full coverage on We finally have data on the rabbinate. The reactions are a dataset, too. - eJewishPhilanthropy

We finally have data on the rabbinate. The reactions are a dataset, too.  eJewishPhilanthropy

We finally have data on the rabbinate. The reactions are a dataset, too. - eJewishPhilanthropy

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA - PR Newswire

Click here to get full coverage on ATRA’s 'Judicial Hellhole' Report Lacks Integrity, Should Not be Treated as News - Law.com

ATRA’s 'Judicial Hellhole' Report Lacks Integrity, Should Not be Treated as News  Law.com

ATRA’s 'Judicial Hellhole' Report Lacks Integrity, Should Not be Treated as News - Law.com

Click here to get full coverage on Anti-inflammatory 25(OH)D3, a natural steroid hormone, may complement all-trans retinoic acid therapy for differentiation syndrome in acute promyelocytic leukemia | Cell Death & Disease - Nature

Anti-inflammatory 25(OH)D3, a natural steroid hormone, may complement all-trans retinoic acid therapy for differentiation syndrome in acute promyelocytic leukemia | Cell Death & Disease  Nature

Anti-inflammatory 25(OH)D3, a natural steroid hormone, may complement all-trans retinoic acid therapy for differentiation syndrome in acute promyelocytic leukemia | Cell Death & Disease - Nature

Click here to get full coverage on We Might See A Profit From Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Soon - simplywall.st

We Might See A Profit From Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Soon  simplywall.st

We Might See A Profit From Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Soon - simplywall.st

Click here to get full coverage on Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel - ChartMill

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel  ChartMill

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel - ChartMill

Click here to get full coverage on With Atara Biotherapeutics Stock Surging, Have You Considered The Downside? - Trefis

With Atara Biotherapeutics Stock Surging, Have You Considered The Downside?  Trefis

With Atara Biotherapeutics Stock Surging, Have You Considered The Downside? - Trefis

Click here to get full coverage on Breakthrough: FDA Fast-Tracks First-Ever Cell Therapy for Fatal Post-Transplant Cancer - Stock Titan

Breakthrough: FDA Fast-Tracks First-Ever Cell Therapy for Fatal Post-Transplant Cancer  Stock Titan

Breakthrough: FDA Fast-Tracks First-Ever Cell Therapy for Fatal Post-Transplant Cancer - Stock Titan

Click here to get full coverage on A High Holiday helpline for rabbis is flooded with millennial calls - The Forward

A High Holiday helpline for rabbis is flooded with millennial calls  The Forward

A High Holiday helpline for rabbis is flooded with millennial calls - The Forward

Click here to get full coverage on Airbus A320 ATRA Flies in IOC Configuration Ahead of Eurofighter’s AESA Radar Testing - The Aviationist

Airbus A320 ATRA Flies in IOC Configuration Ahead of Eurofighter’s AESA Radar Testing  The Aviationist

Airbus A320 ATRA Flies in IOC Configuration Ahead of Eurofighter’s AESA Radar Testing - The Aviationist

Click here to get full coverage on Review: ‘Iraq, But Funny’ at Lookingglass Theatre is a stunning debut in need of an edit - Chicago Tribune

Review: ‘Iraq, But Funny’ at Lookingglass Theatre is a stunning debut in need of an edit  Chicago Tribune

Review: ‘Iraq, But Funny’ at Lookingglass Theatre is a stunning debut in need of an edit - Chicago Tribune

Click here to get full coverage on Atara Biotherapeutics Provides a Business Update - ChartMill

Atara Biotherapeutics Provides a Business Update  ChartMill

Atara Biotherapeutics Provides a Business Update - ChartMill

Click here to get full coverage on Karmel Mall, once a bustling center of community, falls silent - Minnesota Reformer

Karmel Mall, once a bustling center of community, falls silent  Minnesota Reformer

Karmel Mall, once a bustling center of community, falls silent - Minnesota Reformer

Click here to get full coverage on ATRA FORM Brings Its Design Universe to New York’s Clarkson Street - dscene magazine

ATRA FORM Brings Its Design Universe to New York’s Clarkson Street  dscene magazine

ATRA FORM Brings Its Design Universe to New York’s Clarkson Street - dscene magazine

Click here to get full coverage on High-Risk APL: Targeted Therapy Outshines Chemo - Medscape

High-Risk APL: Targeted Therapy Outshines Chemo  Medscape

High-Risk APL: Targeted Therapy Outshines Chemo - Medscape

Click here to get full coverage on Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress - Business Wire

Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress  Business Wire

Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress - Business Wire

Click here to get full coverage on 1/12/2026 Market Update - Winners: CRAN, EVTV, LVLU - Losers: ATRA, LYRA, NBY - S&P 500: 0.2% - Trefis

1/12/2026 Market Update - Winners: CRAN, EVTV, LVLU - Losers: ATRA, LYRA, NBY - S&P 500: 0.2%  Trefis

1/12/2026 Market Update - Winners: CRAN, EVTV, LVLU - Losers: ATRA, LYRA, NBY - S&P 500: 0.2% - Trefis

Click here to get full coverage on Atara Biotherapeutics (ATRA) Transfers Key FDA Application to Pi - GuruFocus

Atara Biotherapeutics (ATRA) Transfers Key FDA Application to Pi  GuruFocus

Atara Biotherapeutics (ATRA) Transfers Key FDA Application to Pi - GuruFocus

Click here to get full coverage on Atara Biotherapeutics (ATRA) Shares Plunge After FDA Setback - GuruFocus

Atara Biotherapeutics (ATRA) Shares Plunge After FDA Setback  GuruFocus

ATRA

Price Chart

Key Statistics

Technicals

About ATRA

Latest News

FDA to review new tab-cel data after Atara partner seeks clarity - Stock Titan

Precision Trading with Atara Biotherapeutics Inc. (ATRA) Risk Zones - Stock Traders Daily

Atara (ATRA) Schedules FDA Meeting to Address CRL for Tabelecleu - GuruFocus

Advanced Charts

Top Gainers

Top Losers